1. In Vivo
  2. >>Deal-Making

Biopharma Quarterly Dealmaking Statistics, Q3 2017

A look at financing, M&A and alliance activity July–September 2017

 
• By Amanda Micklus and Maureen Riordan

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

Quarterly Stats_1200x675

Third-quarter 2017 biopharma financing reached $12.5 billion, just a 6% decrease from the previous quarter's $13.4 billion. (See Exhibit 1.) The most money was raised in the follow-on public offering category, which accounted for nearly half (49%) of the Q3 dollar volume. The average deal value increased to $124 million (versus $85 million in Q2), attributed to 20 of the 50 financings completed having a value of $100 million or more. The largest was Incyte Corp.'s $650 million September FOPO; part of the proceeds will fund R&D activities. [See Deal] In addition to Incyte's marketed oncology therapies Jakafi (ruxolitinib) and Iclusig (ponatinib; to which Incyte has exclusive European right per a 2016 deal with Ariad Pharmaceuticals Inc.[See Deal]), it has many more candidates in development across various therapeutic areas, including cancer, dermatology and immunology, with multiple partnered programs.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.